Syntekabio Expands Supercomputer Facilities to 5,000 Units... Accelerating AI Drug Development Automation

AI new drug development specialist Syntekabio (CEO Jeong Jong-seon) announced on the 4th that it has expanded its supercomputing facilities for AI new drug development from 3,000 units to 5,000 units.

Syntekabio recently added 1,000 central processing units (CPUs) and 1,000 graphics processing units (GPUs) to its Daejeon Dungok AI Bio Supercomputing Center (ABS Center), which it operates independently. This is approximately 1.67 times the previous scale. As a result, the company has established a total of 5,000 supercomputing infrastructure units.

The newly expanded 5,000 supercomputing units support performance capable of discovering 50 new drug candidates (Hits) per month through simple calculations, while simultaneously analyzing 7,200 whole genome sequences (WGS) monthly. This represents about a 70% performance improvement compared to the existing supercomputers.

In light of recent collaborations between NVIDIA and Recursion, supercomputing infrastructure is increasingly recognized as an essential resource in AI new drug development. This is because large-scale computations of vast data are indispensable for processes such as ▲protein-drug binding structures ▲drug design ▲drug optimization ▲candidate compound derivation. Syntekabio is the only company in Korea equipped with supercomputing facilities for AI new drug development.

The company expects that the supercomputing facilities, which have completed stabilization work, combined with a cloud-based automated system, will accelerate the establishment of a factory-level platform for AI new drug candidate generation.

The factory-level platform for AI new drug candidate generation is an automated process that enables continuous progression of candidate development by utilizing the synthetic new drug candidate discovery AI platform 'DeepMatcher' based on supercomputing and cloud infrastructure. The automation and optimization of the discovery process are characterized by shortening the new drug development period and improving resource efficiency.

Through the automated AI new drug candidate discovery system, Syntekabio is building an effective compound database (DB) and has launched the STB Launchpad service to actively pursue global partnerships. When starting the AI new drug candidate discovery process from the pre-derived effective compound DB, clients benefit from significantly reduced time compared to before. The company plans to provide innovative AI new drug services never seen before, allowing clients to experience tangible benefits.

Jeong Jong-seon, CEO of Syntekabio, said, “This supercomputer expansion was carried out in line with participation in major global conferences and business expansion in the first half of this year, following the completion of the ABS Center in October last year.” He added, “The supercomputer expansion will play a major role in the advancement and efficient service provision of Syntekabio’s AI drug platforms, such as ‘DeepMatcher®’, ‘NEO-ARS®’, and ‘Ab-ARS™’, which are attracting attention both domestically and internationally.”

This content was produced with the assistance of AI translation services.